Beta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts

Heart failure is a multifactorial disease that affects an estimated 38 million people worldwide. Current pharmacotherapy of heart failure with reduced ejection fraction (HFrEF) includes combination therapy with angiotensin-converting enzyme inhibitors (ACEi) and β-adrenergic receptor blockers (β-AR...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorrentino, Andrea, Bagwan, Navratan, Linscheid, Nora, Poulsen, Pi C., Kahnert, Konstantin, Thomsen, Morten B., Delmar, Mario, Lundby, Alicia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934364/
https://www.ncbi.nlm.nih.gov/pubmed/35306519
http://dx.doi.org/10.1038/s41598-022-08534-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934364/
https://www.ncbi.nlm.nih.gov/pubmed/35306519
http://dx.doi.org/10.1038/s41598-022-08534-0

Ejemplares similares